Bulgaria
Tuberculosis profile
| High MDR-TB burden |
Population  2012 7.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.15–0.15) 2 (2–2.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Prevalence  (includes HIV+TB) 3.1 (1.3–5.8) 43 (17–80)
Incidence  (includes HIV+TB) 2.3 (2–2.6) 32 (28–36)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.07 (0.06–0.08)
Case detection, all forms (%) 90 (79–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 741 (38) Relapse 115 (37)
Smear-negative 579 (29) Treatment after failure 29 (9)
Smear-unknown / not done 39 (2) Treatment after default 26 (8)
Extrapulmonary 606 (31) Other 144 (46)
Other 1 (<1)      
Total new 1 966   Total retreatment 314  
           
Other (history unknown) 0        
Total new and relapse 2 081   Total cases notified 2 280  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.6 2.0 1.4
Age < 15 0 9 167
Laboratories 2012
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 21.3
Drug susceptibility testing (per 5 million population) 9.6
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 85  
Retreatment 66  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 513 (66)
HIV-positive TB patients 3 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.3 (1.3–3.8) 23 (17–31)
MDR-TB cases among notified pulmonary
TB cases
32 (18–51) 73 (52–98)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 687 (71%) 142 (45%) 829
Laboratory-confirmed MDR-TB cases 16 33 49
Patients started on MDR-TB treatment     36
Financing TB control 2013
National TB programme budget (US$ millions) 16
% Funded domestically 85%
% Funded internationally 15%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data